Kodiak Sciences' eye disease drug matches Eylea in Phase 3, sending stock soaring

Kodiak Sciences reported that two of its eye‑disease candidates performed on par with aflibercept (Eylea) in a pivotal Phase 3 trial. The data suggest comparable efficacy in treating the targeted retinal condition.

The news sparked a sharp rally in Kodiak's shares, with the stock roughly doubling after the announcement. Investors appear to be rewarding the positive trial outcome and the potential market opportunity.

With the trial results in hand, the company plans to file for FDA approval of one of the assets later this year, aiming to bring a new treatment option to patients and capture market share from existing therapies.